These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33201)

  • 1. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.
    Pieniaszek HJ; Resetarits DE; Wilferth WW; Blumenthal HP; Bates TR
    J Clin Pharmacol; 1979 Jan; 19(1):39-45. PubMed ID: 33201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
    Taggart AJ; McDermott BJ; Roberts SD
    Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake.
    Dhôte R; Bergmann JF; Leglise P; Chassany O; Elkharrat D; Conort O; Caulin C
    Clin Pharmacol Ther; 1995 Apr; 57(4):461-70. PubMed ID: 7712676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the intestinal flora in the acetylation of sulfasalazine metabolites.
    Dull BJ; Salata K; Goldman P
    Biochem Pharmacol; 1987 Nov; 36(21):3772-4. PubMed ID: 2890356
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of enteric-coated penicillamine tablets.
    Chambliss WG; Chambliss DA; Cleary RW; Jones AB; Harland EC; Kibbe AH
    J Pharm Sci; 1984 Sep; 73(9):1215-9. PubMed ID: 6333505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption of enteric and non-enteric coated prednisolone tablets.
    Hulme B; James VH; Rault R
    Br J Clin Pharmacol; 1975 Aug; 2(4):317-20. PubMed ID: 1233990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History of enteric coated sulfasalazine in rheumatoid arthritis.
    Pinals RS
    J Rheumatol Suppl; 1988 Sep; 16():1-4. PubMed ID: 2903922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
    Corey AE; Rose GM; Conklin JD
    J Int Med Res; 1990; 18(6):441-53. PubMed ID: 1981363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enteric coated quinidine compared to sustained release preparations during repeated administration.
    Bakke OM; Aanderud L; Aslaksen A
    Acta Med Scand; 1980; 207(3):183-7. PubMed ID: 7368984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.